CLP 290 is a carbamate prodrug form of the K+/Cl- cotransporter 2 (KCC2) activator CLP 257 .1 It increases the mechanical paw withdrawal threshold in a rat model of peripheral nerve injury and reverses morphine-induced hyperalgesia in rats when administered at a dose of 100 mg/kg.1,2 CLP 290 (35 mg/kg) also restores stepping ability, as well as increases body weight support and stride length, in a mouse model of paralysis induced by staggered spinal lesions.3
1.Gagnon, M., Bergeron, M.J., Lavertu, G., et al.Chloride extrusion enhancers as novel therapeutics for neurological diseasesNat. Med.19(11)1524-1528(2013) 2.Ferrini, F., Lorenzo, L.-E., Godin, A.G., et al.Enhancing KCC2 function counteracts morphine-induced hyperalgesiaSci. Rep.7(1)3870(2017) 3.Chen, B., Li, Y., Yu, B., et al.Reactivation of dormant relay pathways in injured spinal cord by KCC2 manipulationsCell174(3)521-535(2018)